middel ear injection of steroid for sudden deafness

Intratympanic steroid injection for sudden sesorineural hearing loss: a prospective observational study - Intratympanic steroid injection for sudden sesorineural hearing loss

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038815

Enrollment

Registered

2020-01-01

Start date

2020-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden sensorineural hearing loss

Interventions

intratympanic injection of steroids dexamethasone 5mg/ml one administration per week.Total of 4 administrations

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1,age above 20 2,infomed consent by written documents 3,within 6 weeks from the onset 4, hearing loss of grade 3 or 4 ineligible for systemic steroids or unrecovered after systemic steroids

Exclusion criteria

Exclusion criteria: 1, history of allergy to dexamethasone 2, history of allergy to EMLA cream 3, active infection in the middele ear

Design outcomes

Primary

Measure	Time frame
improvement in pure tone audiometry at the end of the therapy, one month after the treatment, and 3months after the treatment	—

Secondary

Measure	Time frame
adverse events, such as tympanic membrane perforation	—

Countries

Japan

Contacts

Public Contactyukinori takenaka

Kansai medical hospital department of otolaryngology

ysktakenaka@gmail.com0668361199

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026